CRUKD/24/002 A CRUK Phase II open label trial in participants with metastatic pancreatic adenocarcinoma (PDAC) of ginisortamab (UCB6114), a first in class anti-gremlin1 mAb, given iv with 1st line SOC nab-paclitaxel & gemcitabine or in combination with MEK inhibitor maintenance therapy
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.